Nuveen LLC Invests $670,000 in OraSure Technologies, Inc. $OSUR

Key Points

• Nuveen LLC has invested approximately $670,000 in OraSure Technologies, acquiring 198,915 shares and representing 0.26% of the company's total shares.
• A significant percentage, 93.50%, of OraSure Technologies' stock is owned by institutional investors and hedge funds, revealing strong institutional interest in the company.
• OraSure Technologies currently has a consensus rating of "Hold" from analysts, with a price target set at $3.00 per share.

Nuveen LLC purchased a new stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) during the 1st quarter, according to the company in its most recent filing with the SEC. The fund purchased 198,915 shares of the medical instruments supplier's stock, valued at approximately $670,000. Nuveen LLC owned about 0.26% of OraSure Technologies as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently made changes to their positions in OSUR. Tower Research Capital LLC TRC raised its position in shares of OraSure Technologies by 202.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,821 shares of the medical instruments supplier's stock worth $28,000 after buying an additional 5,234 shares during the period. Raymond James Financial Inc. purchased a new position in OraSure Technologies during the 4th quarter worth approximately $37,000. Gotham Asset Management LLC acquired a new stake in shares of OraSure Technologies in the 4th quarter valued at $43,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in OraSure Technologies in the 1st quarter worth $49,000. Finally, Simplicity Wealth LLC bought a new position in shares of OraSure Technologies during the 1st quarter worth about $53,000. Institutional investors and hedge funds own 93.50% of the company's stock.

OraSure Technologies Stock Down 0.5%

Shares of NASDAQ OSUR traded down $0.02 during midday trading on Monday, reaching $3.22. 118,610 shares of the stock were exchanged, compared to its average volume of 753,089. The firm has a 50-day simple moving average of $3.09 and a two-hundred day simple moving average of $3.07. The firm has a market cap of $235.15 million, a price-to-earnings ratio of -4.80 and a beta of 0.44. OraSure Technologies, Inc. has a twelve month low of $2.36 and a twelve month high of $4.60.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on OSUR shares. Wall Street Zen upgraded shares of OraSure Technologies from a "sell" rating to a "hold" rating in a report on Saturday, May 17th. Evercore ISI reiterated an "in-line" rating and set a $3.00 target price on shares of OraSure Technologies in a research report on Monday, May 19th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat.com, OraSure Technologies currently has an average rating of "Hold" and a consensus target price of $3.00.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.